Bone Biologics Corporation Regains Compliance with Nasdaq Listing Requirements After Meeting Minimum Bid Price Threshold

Reuters06-27

Bone Biologics Corporation Regains Compliance with Nasdaq Listing Requirements After Meeting Minimum Bid Price Threshold

Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, has announced that it has regained compliance with Nasdaq's continued listing requirements. Previously, on April 7, 2025, the company was notified by Nasdaq that it was not in compliance with the minimum bid price requirement, as its common stock failed to maintain a closing bid price of at least $1.00 for 30 consecutive business days. To address this issue, Bone Biologics was required to achieve a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, a milestone it successfully reached on June 24, 2025. With this achievement, Bone Biologics is now in compliance with all applicable Nasdaq listing standards, and its common stock will continue to be listed on the Nasdaq Capital Market.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bone Biologics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250626668160) on June 26, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2546942759?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-27 04:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2546942759","market":"fut","top_or_hot":-1,"title":"Bone Biologics Corporation Regains Compliance with Nasdaq Listing Requirements After Meeting Minimum Bid Price Threshold","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bone Biologics Corporation Regains Compliance with Nasdaq Listing Requirements After Meeting Minimum Bid Price Threshold\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, has announced that it has regained compliance with Nasdaq's continued listing requirements. Previously, on April 7, 2025, the company was notified by Nasdaq that it was not in compliance with the minimum bid price requirement, as its common stock failed to maintain a closing bid price of at least $1.00 for 30 consecutive business days. To address this issue, Bone Biologics was required to achieve a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, a milestone it successfully reached on June 24, 2025. With this achievement, Bone Biologics is now in compliance with all applicable Nasdaq listing standards, and its common stock will continue to be listed on the Nasdaq Capital Market.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bone Biologics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250626668160) on June 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bone Biologics Corporation Regains Compliance with Nasdaq Listing Requirements After Meeting Minimum Bid Price Threshold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBone Biologics Corporation Regains Compliance with Nasdaq Listing Requirements After Meeting Minimum Bid Price Threshold\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-27 04:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Bone Biologics Corporation Regains Compliance with Nasdaq Listing Requirements After Meeting Minimum Bid Price Threshold\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, has announced that it has regained compliance with Nasdaq's continued listing requirements. Previously, on April 7, 2025, the company was notified by Nasdaq that it was not in compliance with the minimum bid price requirement, as its common stock failed to maintain a closing bid price of at least $1.00 for 30 consecutive business days. To address this issue, Bone Biologics was required to achieve a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, a milestone it successfully reached on June 24, 2025. With this achievement, Bone Biologics is now in compliance with all applicable Nasdaq listing standards, and its common stock will continue to be listed on the Nasdaq Capital Market.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bone Biologics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250626668160) on June 26, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nNDL8XhlRD:1","article_id":"2546942759","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2546942759","pubTimestamp":1750969210,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, has announced that it has regained compliance with Nasdaq's continued listing requirements. Previously, on April 7, 2025, the company was notified by Nasdaq that it was not in compliance with the minimum bid price requirement, as its common stock failed to maintain a closing bid price of at least $1.00 for 30 consecutive business days. To address this issue, Bone Biologics was required to achieve a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, a milestone it successfully reached on June 24, 2025. With this achievement, Bone Biologics is now in compliance with all applicable Nasdaq listing standards, and its common stock will continue to be listed on the Nasdaq Capital Market.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BBLG":"Bone Biologics Corp"},"translate_title":"Bone Biologics Corporation在达到最低投标价格门槛后重新遵守纳斯达克上市要求","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBLG":0.9},"content_text":"Bone Biologics Corporation Regains Compliance with Nasdaq Listing Requirements After Meeting Minimum Bid Price Threshold\n    \n\n        Bone Biologics Corporation, a developer of orthobiologic products for spine fusion markets, has announced that it has regained compliance with Nasdaq's continued listing requirements. Previously, on April 7, 2025, the company was notified by Nasdaq that it was not in compliance with the minimum bid price requirement, as its common stock failed to maintain a closing bid price of at least $1.00 for 30 consecutive business days. To address this issue, Bone Biologics was required to achieve a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, a milestone it successfully reached on June 24, 2025. With this achievement, Bone Biologics is now in compliance with all applicable Nasdaq listing standards, and its common stock will continue to be listed on the Nasdaq Capital Market.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bone Biologics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20250626668160) on June 26, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2546942759","isCrawlerRequest":true}